1. Home
  2. LC vs DVAX Comparison

LC vs DVAX Comparison

Compare LC & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LendingClub Corporation

LC

LendingClub Corporation

HOLD

Current Price

$19.26

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$15.38

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LC
DVAX
Founded
2006
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.3B
IPO Year
2014
2004

Fundamental Metrics

Financial Performance
Metric
LC
DVAX
Price
$19.26
$15.38
Analyst Decision
Buy
Hold
Analyst Count
6
5
Target Price
$22.67
$26.50
AVG Volume (30 Days)
1.6M
3.7M
Earning Date
01-27-2026
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
93.62
N/A
EPS
0.89
N/A
Revenue
$1,296,102,000.00
$330,514,000.00
Revenue This Year
N/A
$24.63
Revenue Next Year
$16.49
$15.85
P/E Ratio
$21.24
N/A
Revenue Growth
16.98
26.73
52 Week Low
$7.90
$9.20
52 Week High
$20.94
$15.49

Technical Indicators

Market Signals
Indicator
LC
DVAX
Relative Strength Index (RSI) 53.51 88.85
Support Level $18.33 $10.78
Resistance Level $20.30 $15.43
Average True Range (ATR) 0.61 0.16
MACD -0.12 0.46
Stochastic Oscillator 41.16 97.74

Price Performance

Historical Comparison
LC
DVAX

About LC LendingClub Corporation

LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: